News

A substantial discount would be needed to meet cost-effectiveness thresholds.

As COVID-19 precautions are dwindling throughout the world, this upcoming flu season could re-heighten those precautions.

The FDA would like to see additional data on clinical benefit for patients with anal cancer.

Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.

Jennifer Sheets, CEO of Interim Healthcare and Caring Brands International, says a preventable hospital error led to her father’s death: “My commitment and passion for high-quality, process-driven healthcare (are) still greatly fueled by the horrific event that absolutely didn’t need to happen.”

Few ACOs in their early years made progress on the actual cost drivers in healthcare, including specialty services costs, clinical standards of care, and acute care.

Current drug shortages based on FDA data, prepared by Formulary Watch.

Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.

New vaccine for pneumococcal disease, an sNDA approved based on real-world data, a new therapy for skin and muscle disease, Keytruda combination receives full approval in endometrial cancer, a new diabetes therapy is approved, and another JAK inhibitor misses PDUFA date round out this week’s FDA news.

Engaging with payers in collaborative arrangements is critical for achieving quality outcomes at lower cost, while ensuring financial health for providers during good times and bad.

When Medicare D plans do provide coverage for first generics, they are often placed on non-generic tiers.

Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Summit Health’s Chief Quality Officer Ashish D. Parikh, MD, and Chief of Population Health Jamie Reedy, MD, in this episode of Tuning In to the C-Suite. In the conversation, the three discussed value-based care programs and contracts within Summit Health and what it takes to invest and implement these programs into your healthcare organization.

VP of social responsibility says the health insurer wants to “broaden our scope a little bit” and factor in community voices.

The accreditation is effective through July 2024.

Insurers make acquisitions as pandemic adoption of virtual care delivery becomes the norm.

Eric Hunter, MBA, CEO of CareOregon, say that “building relationships with people through professional organizations and prior assignments kept me on the radar for the right opportunities.”

The FDA had approved Kadmon's therapy for graft-versus-host disease July 16.

The therapy is approved for both adults and children.

Azstarys is approved to treat patients 6 years and older.

Most of the suspected cases of myocarditis developed after the second dose of the vaccine and were among younger males.

After having thrived in a fee-for-service healthcare system, can chronic disease specialists be enticed to switch?

Sixty percent of patients likely to move forward with a healthcare decision not recommended by their physician, according to a TrialJectory Survey.

Wynzora is a cream-based, fixed dose combination of calcipotriene and betamethasone for topical treatment of psoriasis.

This is being done in coordination with the FDA to address the shortage created by the recall of Chantix. UPDATE: Pfizer has expanded its recall of Chantix from nine lots to 12 lots.

Ramin Davidoff, M.D., co-CEO of the Permanente Federation, has applied lessons he learned as a child. “There is no substitute for working hard and to always treat your people kindly, professionally and respectfully.”

The company’s stock began dropping on Tuesday with analyst expectation the FDA will issue a Complete Response Letter for tenapanor, its chronic kidney disease therapy.

Eight out of 10 covered U.S. commercial lives now have access to the H. pylori therapy.

Oscar and Bright Health, with their retail orientation, are attracting investment, adding members, entering partnerships and making acquisitions.